Literature DB >> 6995622

Experience with Gleason's histopathologic grading in prostatic cancer.

S A Kramer, J Spahr, C B Brendler, J F Glenn, D F Paulson.   

Abstract

The inaccuracy of clinical staging as a predictor of the biologic potential of prostatic cancer has prompted evaluation of additional methods of assessment. We reviewed 228 patients with prostatic adenocarcinoma who presented during a 4-year period. Of the 228 patients 144 with no detectable bony disease underwent staging pelvic lymphadenectomy with or without preliminary bilateral pedal lymphangiography. Histopathologic specimens of the primary diagnostic prostatic biopsy were classified with Gleason's grading system of tumor differentiation. Of the patients with Gleason's sum of 8, 9 or 10, 93 per cent had regional nodal metastases, regardless of preliminary clinical stage. Furthermore, no patient with Gleason's sum of 2, 3 or 4 had nodal metastatic disease. The incidences of falsely positive and falsely negative lymphangiograms were 29 and 35 per cent, respectively, reflecting the unreliability of pedal lymphangiography to predict nodal involvement accurately in patients with prostatic cancer. The Gleason system of histopathologic grading was reliable and reproducible, and afforded an accurate prediction of the surgical stage of disease.

Entities:  

Mesh:

Year:  1980        PMID: 6995622     DOI: 10.1016/s0022-5347(17)55381-1

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens.

Authors:  Burkhard Helpap; Lars Egevad
Journal:  Virchows Arch       Date:  2006-11-08       Impact factor: 4.064

2.  Urology-important advances in clinical medicine: computerized tomography, lymphangiography and Gleason scores for staging prostatic adenocarcinoma.

Authors:  R R Torrey; M Janseen; V Ching
Journal:  West J Med       Date:  1983-04

3.  Aneuploidy of glandular epithelial cells in histologically normal prostate glands.

Authors:  T I Malinin; F J Hornicek; N L Block; G I Malinin
Journal:  Experientia       Date:  1988-03-15

Review 4.  Stage T1c prostate cancer: defining the appropriate staging evaluation and the role for pelvic lymphadenectomy.

Authors:  M C Beduschi; R Beduschi; J E Oesterling
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

5.  Detection of the apoptosis-suppressing oncoprotein bc1-2 in hormone-refractory human prostate cancers.

Authors:  M Colombel; F Symmans; S Gil; K M O'Toole; D Chopin; M Benson; C A Olsson; S Korsmeyer; R Buttyan
Journal:  Am J Pathol       Date:  1993-08       Impact factor: 4.307

6.  Histopathological pattern in prostatic adenocarcinomas: is it a prognostic criterion?

Authors:  K Bircan; I Başar; A Ergen; S Tekgül; G Ozbay; H A Ozen
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

7.  Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.

Authors:  Ying-Li Lin; Pei-Gen Xie; Li Wang; Jian-Guo Ma
Journal:  Med Sci Monit       Date:  2014-08-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.